Jorgen Matz serves as the Head of Global Clinical Quality & Pharmacovigilance at Insud Pharma, where he leverages over two decades of extensive experience in the pharmaceutical industry to drive excellence in clinical development and safety monitoring. His role encompasses the management of clinical quality...
Jorgen Matz serves as the Head of Global Clinical Quality & Pharmacovigilance at Insud Pharma, where he leverages over two decades of extensive experience in the pharmaceutical industry to drive excellence in clinical development and safety monitoring. His role encompasses the management of clinical quality across the company's diverse R&D portfolio, ensuring compliance with Good Clinical Practice (GCP) standards while fostering a culture of quality and safety. Jorgen oversees global pharmacovigilance operations across five distinct business units, including Chemo, Exeltis, mAbxience, Xiromed, and Vetfarma, where he plays a pivotal role in the strategic oversight of drug safety and risk management.
A key aspect of Jorgen's responsibilities involves meticulous planning and tracking of budgeting and resource allocations, which is essential for optimizing operational efficiency in a challenging economic landscape. His ability to navigate complex business operations is complemented by his commitment to effective cross-functional teamwork, enabling collaboration among diverse teams and stakeholders on a global, regional, and affiliate level. Jorgen’s expertise in clinical trials, drug development, and clinical pharmacology positions him as a visionary leader capable of providing scientific support and strategic guidance to line managers and pharmacovigilance staff.
Throughout his career, Jorgen has demonstrated a profound understanding of the intricacies of drug discovery and development, making him a valuable asset in advancing Insud Pharma's mission to deliver innovative healthcare solutions. His dedication to enhancing clinical quality and pharmacovigilance practices not only safeguards patient safety but also ensures that the company remains at the forefront of the pharmaceutical industry.
